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Pancreatic cancer associated with obesity
and diabetes: an alternative approach for
its targeting
Ramesh Pothuraju1, Satyanarayana Rachagani1, Wade M. Junker1,2, Sanjib Chaudhary1, Viswanathan Saraswathi3,
Sukhwinder Kaur1 and Surinder K. Batra1,4,5*

Abstract
Background: Pancreatic cancer (PC) is among foremost causes of cancer related deaths worldwide due to generic
symptoms, lack of effective screening strategies and resistance to chemo- and radiotherapies. The risk factors associated
with PC include several metabolic disorders such as obesity, insulin resistance and type 2 diabetes mellitus (T2DM).
Studies have shown that obesity and T2DM are associated with PC pathogenesis; however, their role in PC initiation and
development remains obscure.
Main body: Several biochemical and physiological factors associated with obesity and/or T2DM including adipokines,
inflammatory mediators, and altered microbiome are involved in PC progression and metastasis albeit by
different molecular mechanisms. Deep understanding of these factors and causal relationship between factors
and altered signaling pathways will facilitate deconvolution of disease complexity as well as lead to development of
novel therapies. In the present review, we focuses on the interplay between adipocytokines, gut microbiota,
adrenomedullin, hyaluronan, vanin and matrix metalloproteinase affected by metabolic alteration and pancreatic tumor
progression.
Conclusions: Metabolic diseases, such as obesity and T2DM, contribute PC development through altered metabolic
pathways. Delineating key players in oncogenic development in pancreas due to metabolic disorder could be a
beneficial strategy to combat cancers associated with metabolic diseases in particular, PC.
Keywords: Pancreatic cancer, Obesity, Insulin resistance, Diabetes, Adiponectin, Leptin, Gut microbiota, Inflammation

Background
The pancreas contains exocrine and endocrine cells. The
endocrine cells secrete insulin, glucagon, and somatostatin, whereas exocrine cells are involved in the secretion of digestive enzymes. Pancreatic cancer (PC) is
lethal malignancy and approximately, 95% of PC has an
exocrine cell origin. It is very difficult to diagnose at an
early stage due to the lack of symptoms and deep retroperitoneal of pancreas. This PC type is commonly
known as pancreatic ductal adenocarcinoma (PDAC),
with a 5-year survival rate of ~7.2% in the United States
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(US) [1]. PC has become the third leading cause of
cancer-related deaths with an estimated new cases of
55,440 and deaths of 44,330 in 2018 [2]. The lifetime
risk of developing PC in any one person is 1.6% and it is
expected to surpass colon cancer in mortality by year
2030 [3]. PC is frequently diagnosed at an advanced
stage, when the cancer has metastasized to distant organs like the liver, lung, lymph node and peritoneal cavity [4]. Unfortunately by the clinical presentation, 85% of
the tumors are unresectable [5, 6] which translates to
poor prognosis and high mortality in the absence of effective chemo- and radiotherapies. Risk factors for
PDAC include age (high percentage in elderly), sex (high
incidence in men), gene mutations, cigarette smoking
(nearly one quarter of all PC cases), obesity, chronic pancreatitis, and diabetes [7, 8].
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In PC, pancreatic stellate cells form a dense stromal
tissue, which is referred to as a desmoplastic reaction.
Stellate cells are responsible for limiting vascularization,
which leads to hypoxia, tumor progression, invasion,
and metastasis [9–13]. In PC, a compendium of mutations occur in various oncogenes like Kirsten rat sarcoma viral oncogene homolog (KRAS) and tumor
suppressor genes (INK4A/p16, Tp53 and SMAD4) [14].
Mutations in the KRAS oncogene, observed in more
than 90% of PC tumors, leads to constitutively active
Ras protein that results in uncontrolled cell proliferation.
Further, inactivating mutations in INK4A/p16 and Tp53
results in the loss of cell cycle and apoptotic regulation
[4]. Differential expression of epidermal growth factor
receptor (EGFR), mucins (MUC1, MUC6 and MUC5AC)
and matrix metalloproteinases (MMPs) occurs during
precursor development [15]. Mutations in INK4A/p16
(90%) appear in PanIN-2, whereas Tp53 (85%) and
SMAD4 (55%) mutations are found in PanIN-3. Since
PanINs represent precancerous ductal lesions, these mutations are considered early molecular biomarkers for
PC [15]. A combination of biomarkers (EGFR, ERK,
SIAH, Ki67 and HIF-α) can predict survival rates for patients with resectable PC. In fact, a combination of these
biomarkers is more strongly associated with pathological
features including tumor size, tumor grade, margin and
lymph node status compared to a single marker [7, 16,
17]. In a multicenter study, to differentiate PC from
chronic pancreatitis and their benign controls, mucin
(MUC5AC) alone or in combination with CA19-9 could
be a potential diagnostic/prognostic biomarker [18].
Due to generic symptoms (weight loss, fatigue, jaundice, abdominal pain and nausea) common across multiple other pathologies , early identification of PC is
difficult [19, 20]. Recent studies suggest that PC develops from a precursor lesion of <5 mm in diameter
and may take an average of 20 years to metastasize [20].
Therefore, it provides a window of opportunity to diagnose and treat PC if it is detected at an early stage [21].
To date, efforts are being made in multiple directions to
develop early diagnostic test for PC including histopathological tests on fine needle aspirates, serological
tests, imaging (computed tomography/magnetic resonance imaging), and analysis of genetic mutation markers
[21–23]. Regarding PC treatment, gemcitabine (a nucleotide analogue) is the preferred first-line option but
survival is often less than ~5 months. Combination therapy with gemcitabine and erlotinib (an inhibitor of
EGFR) increased the 1-year survival rate to 23% as compared to 17% in the gemcitabine plus placebo group in a
randomized phase III clinical trial [24]. Other drugs such
as folfirinox/nab-paclitaxel with gemcitabine also increase survival [25–27]. In a clinical trial, metastatic PC
patients were treated by administration of folfirinox
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(5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) had shown greater efficacy for metastatic cancer;
however, few limitations were observed due to its cytotoxicity [28]. However, in a systematic study, over 30
years (from 1986 to 2016) weighted median overall survival was improved with folfirinox alone [3]. In addition
to the above chemotherapeutic agents, different treatment options for PC patients includes Capecitabine and
5-fluorouracil (5-FU) along with platinum-based or
other cancer drugs (leucovorin, exatecan, and irinotecan)
[27]. Therefore novel treatment strategies are needed to
improve the overall survival in PC patients.
Obesity, insulin resistance and diabetes

Obesity has become a serious threat worldwide and is
considered an epidemic. It occurs due to changes in lifestyle (physical inactivity, intake of high fat/caloric diet,
high sugar diet) and is also associated with lifestyle including cigarette smoking and alcohol consumption.
Additionally, genetic factors such as mutation in the leptin pathway leads to monogenic obesity while chromosomal abnormalities results in syndromic obesity [29]. In
the body, adipose tissue (AT) plays an important role in
the storage of triglycerides (TG), which come from the
diet. It is classified as brown and white AT, where brown
AT (BAT) is predominantly located in the cervical area
and utilizes TG to generate heat (a process called as
thermogenesis). Disappearance of BAT has been observed during the aging process and recently it has
gained significant attention. White AT is present in the
subcutaneous layer, omentum and retroperitoneal cavity,
where it stores excess fat. According to the lipid burden
hypothesis, AT stores sufficient lipids in the form of
droplets. Excess storage of lipids leads to hypertrophy
(increase in cell size) and hyperplasia (increase in cell
number) [30]. Moreover, in obesity, heavy traffic of lipids
inside the body leads to release of excess TG in the form
of free fatty acids (FFAs) into the circulation. Further,
these FFAs accumulate in non-adipose tissues such as
the pancreas, muscle, liver, heart and kidney, resulting in
insulin resistance and diabetes [31].
Obesity is a multifactorial disease associated with several metabolic disorders including insulin resistance, glucose intolerance, dyslipidemia, and elevated blood
pressure. All these disorders are collectively called metabolic X syndrome [32]. Further, obesity is a strong risk
factor for type 2 diabetes mellitus (T2DM), cardiovascular diseases and even many types of cancers such as pancreatic, hematological, prostate and breast cancers [33].
Recent studies have revealed that obesity and PC are
strongly associated. For instance, a body mass index
greater than 35 is one of the risk factors for PC in both
men and women [33, 34]. Moreover, studies have suggested that both obese mice and patients develop PC
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lesions following an increase in fat mass [35, 36] and
show infiltration of fat cells in the pancreas as a consequence of PC development [37, 38]. Insulin resistance is
a hallmark of T2DM, in which insulin fails to trigger adequate glucose uptake, leading to accumulation of circulatory glucose as well as increased insulin levels. These
increased insulin levels in T2DM patients may be associated with PC growth by binding to its receptors located
on the pancreas. For example, we still don’t know if the
insulin resistance that characterizes T2DM promotes PC
or if the reverse is true (Fig. 1). In the present review, we
have attempted to compress all the available literature
on obesity-and diabetes-associated molecules involved in
PC development. Several molecules have been characterized in obesity-associated PC, whereas less is known
about factors unique to diabetes-associated PC. These
molecules are expected to be the focus for future investigations of the molecular oncology of cancer.
Obesity associated pancreatic ductal adenocarcinoma

Obesity is associated with pancreatic and other types of
cancers [39–41]. Individuals with abdominal adiposity
have a 50% increased risk of PC development compared
to lean individuals [42]. In the U.S., about 70% of the
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adult population is overweight and has a two-fold increased risk of PC incidence and mortality [39, 42].
However, link between obesity and PC is still not fully
understood [43]. The current theory is that excess TG in
obesity leads to an increase in size and number of adipocytes, which results in devascularization, hypoxia, and
ultimately macrophage infiltration. In this condition, adipocytokines including adiponectin, leptin, tumor necrosis factor-alpha (TNF-α), interleukins, and monocyte
chemoattractant proteins are secreted locally leading to
inflammation. Evidence suggests that increased levels of
adipocytokines, altered gut microbiota, and inflammation are involved in PC progression [39, 44]; thus, this
review focuses on the possible oncogenic roles of these
factors in PC.
Adipocytokines

Besides storing excess energy as TG, AT secretes several
factors regulating energy metabolism in various organs.
These adipokines including adiponectin, leptin, resistin,
and ghrelin play an important role in glucose and lipid
metabolism. Among them, adiponectin and leptin are
the most important and are therefore the focus here in
discussing obesity-associated PC.

Fig. 1 A schematic representation of obesity- and diabetes-associated pancreatic cancer. High fat/caloric intake results in accumulation of excess
fat, which further leads to development of obesity. a. In obesity, adipose tissue releases free fatty acids (FFAs), which enter circulation and accumulate
in the non-adipose tissues such as muscle, liver and pancreas that leads to insulin resistance and diabetes. b. Along with FFAs, adipokines, altered gut
microbiota and inflammatory markers contribute to pancreatic cancer development through unknown mechanisms.
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Adiponectin

Adiponectin is also referred to as AdipoQ, which acts on
several tissues to control energy homeostasis and insulin
sensitivity [45, 46]. It regulates carbohydrate as well as
lipid metabolism through the adenosine monophosphate
-activated protein kinase (AMPK) pathway. The expression of circulatory AdipoQ is decreased in obesity and
diabetes. However, the role of circulating AdipoQ in PC
remains debatable regarding its impact on pancreatic
tumor progression. Adiponectin serve as negative regulator that mediate its function by acting on its two
receptors i.e. AdipoR1 and AdipoR2. Mechanistically,
AdipoQ increases insulin synthesis and secretion by
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preventing apoptosis of pancreatic β-cells through activation of ERK and AKT pathways [47] (Fig. 2). Huang et
al. demonstrated that subcutaneous implant of mouse
pancreatic cell lines (H7 and Panc02) in AdipoQ knockout (APNKO) mice has reduced tumor weight and size
as well as increased apoptosis by up-regulating cleaved
caspase-3 as compared to wild type (WT) littermates. In
addition, knockdown of AdipoR1, the major receptor of
AdipoQ in these mouse cell lines (H7 and Panc02)
followed by subcutaneous injection reduced tumor
weight, size, and expression of Ki-67 (proliferation
marker). Further, AdipoQ was observed to decreases
apoptosis and increases PC cell proliferation and migration

Fig. 2 Adipocytokines mediate pancreatic cancer tumorigenesis by different signaling mechanisms. a. Adiponectin secreted from adipose tissue
binds to its receptor (AdipoR) to activate AKT, MAPK and AMPK pathways, which block the apoptosis of pancreatic cancer cells. b. Similarly, leptin
binding to its receptor (OBR) results in activation of the JAK2/STAT3 pathway, which leads to matrix metalloproteinase-13 activation and eventual
pancreatic cancer metastasis. In addition, OBR also regulates its own expression through hypoxia inducible factor-1, resulting in cancer cell
survival via an unknown mechanism. Moreover, leptin also triggers Notch receptor signaling, which results in activation of its downstream molecules
(survivin and Hey2), thereby increasing cancer cell proliferation.
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by activating the AMPK-Sirt1-PGC1α pathway [48] (Fig. 2).
Similarly, in a case-control study, Dalamaga et al. studied
the blood levels of AdipoQ in PC and control cases both
before and after controlling for age, gender, BMI, smoking
status, alcohol consumption, history of diabetes, and family
history of PC. Higher AdipoQ levels were associated with
PC. At tissue level, utilizing 16 tumor tissues, the authors
observed positive or strong positive expression of AdipoR1
in 87.5% of cases while positive or strong positive expression of AdipoR2 was observed in >97% cases. Based on this,
the investigators suggested to investigate the role of AdipoQ as a marker for early detection of PC. Further, Kadri et
al. observed no correlation between adiponectin levels and
PC [49]. Similarly, Pezzilli et al. did not observe any significant correlation among adiponectin levels and PC at serum
level [50]. However, retrospective and prospective studies
indicate that early detection of low circulatory AdipoQ
levels may or may not be associated with the development
of PC, because single nucleotide polymorphisms of the AdipoQ gene are common [51–54] and the presence of these
SNPs in AdipoQ, but not its receptors, are associated with
altered serum adiponectin levels [55].
Inhibitory role of AdipoQ in halting tumor progression has also been observed [49]. In this regard some
clinical studies suggest that circulating AdipoQ inhibit
tumor cell proliferation by decreasing AKT and beta catenin levels across multiple malignancies (breast, colon
and prostate) [56, 57]. In the case of PC, the molecular
mechanism by which up-regulated AdipoQ levels inhibit
cancer progression is still unclear; possibilities include 1)
increasing insulin sensitivity via phosphorylation of
insulin receptors, which down-regulates insulin/IGF-1
signaling, 2) down-regulating the expression of inflammatory cytokines that inhibit NF-κB activation, 3) directly activating the AMPK pathway to activate the p53
tumor suppressor gene, and 4) promoting cancer cell
apoptosis via peroxisome proliferator-activated receptor
gamma (PPARγ) activation and inhibiting angiogenesis
[58, 59]. One study fed genetically engineered PC mice
(KrasG12D/Pdx-1-Cre) with a calorie-restricted diet and
observed delays in formation of pancreatic intraepithelial
neoplasms (PanIN) [60, 61]. Delayed progression of
PanIN to PDAC was accompanied by increased AdipoQ
and Sirt1 levels as well as decreased mTOR and IGF-1
expression [61]. In another study, Kato et al. incubated
recombinant AdipoQ with the Pan02 murine cell line
and noted decreased cell proliferation and increased
apoptosis at 5 and 10 μg/ml, respectively. Further, orthotopic implantation of Pan02 cell line showed a significant increase in tumor volume by higher vascularization
(more microvessel density) and decreased apoptosis in
AdipoQ knockout mice as compared to WT animal
[58, 62]. Overall, the findings from this study suggested
AdipoQ to be a tumor suppressive role in PC by directly
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inhibiting proliferation and inducing apoptosis [62]. Interestingly, a recent study by Messaggio and co-workers
showed that the decreased expression of AdipoQ receptors in pancreatic tumor tissues as compared to adjacent
normal tissue. To elucidate the role of AdipoQ, its agonist
AdipoRon was applied to both mouse and human cell
lines and was found to inhibit PC tumor growth and
proliferation by down-regulating leptin-induced STAT3
signaling. These results suggest AdipoRon could be a
potential therapeutic agent for PC [63].
Leptin

Leptin was the first adipokine identified in AT in
1993; it controls food intake and energy expenditure
via a feedback mechanism in the brain [64]. After
secretion from AT, leptin enters into circulation and
reaches a level depending upon the AT size [65].
Under normal physiological conditions, leptin decreases appetite and increases fatty acid oxidation
through its receptor (OBR or LEPR). However, in
obesity and diabetes, elevated circulatory levels of
leptin do not drive the same appetite feedback responses [66]. Like AdipoQ, leptin has a role in PC
pathogenesis. In PC tumor cells, leptin binds to both
full-length receptor (OBR1) as well as the short form
(OBRs) to mediate downstream signaling [67]. Leptin
receptor (OBR) and hypoxia inducible factor-1 (HIF-1) are
predominantly co-expressed in PC cell lines and tissues
during hypoxic conditions. HIF-1 binds to the
hypoxia-responsive element (HRE) in the OBR promoter, regulating OBR transcription. Co-expression
of OBR and HIF-1 in PC tissues was associated with
poor prognosis, decreased overall survival and increased metastasis to distant organs in PC patients
(Fig. 2). Silencing of HIF-1 inhibited leptin receptor
expression in PC cells, suggesting that a positive
feedback loop between HIF-1 and leptin/OBR mediates PC progression [67]. In another in vitro study,
recombinant human leptin promoted PC cell migration and invasion but had no effect on proliferation
[68]. The migration of PC cells occurred via the
janus kinase 2 and signal transducer and activator of
transcription 3 (JAK2/STAT3) pathway, which targets
its downstream effector matrix metalloproteinase 13
(MMP13). The in vivo impact of leptin-over expressing PC cells was tested by orthotopic implantation
into athymic nude mice, which led to greater tumor
growth and lymph node metastasis. Over expression
of leptin in PC cells and mouse tumors resulted in
up-regulation of MMP13 levels, suggesting that leptin/MMP13 signaling is important for metastasis. In
addition, MMP13 levels correlated with OBR expression in lymph node metastatic human PC tissues. The authors concluded that PC cell migration, invasion and
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metastasis occur via the JAK2/STAT3/MMP13 pathway
[68] (Fig. 2).
A high fat/caloric diet leads to obesity, insulin resistance and increased leptin levels, all of which contribute
to pancreatic adiposity. The accumulation of lipid molecules into the pancreas leads to activation and deposition of inflammatory cytokines (e.g., interleukin-6),
which potentiate PC cell growth, migration and invasion
[69]. Leptin activates Notch signaling and its receptors,
leading to activation of its downstream molecules (survivin and Hey2) required for PC proliferation (Fig. 2).
Notch signaling also up-regulates stem cell markers
(CD44, CD24 and ESA) in PC cells. Inhibition of leptin
(by IONP-LPrA2) after subcutaneous implantation of
PC cells delayed tumor onset and decreased tumor size
as well as cancer stem cell markers [70]. In another
study by the same group reported that BxPC-3 and
MiaPaCa-2 PC cells were treated in the presence of
5-FU, leptin, notch inhibitor (DAPT) and leptin inhibitor
(IONP-LPrA2). They observed that decreased 5-FU
cytotoxicity (by decreasing pro-apoptotic markers), increased cell proliferation and anti-apoptotic factors was
due to leptin treatment. Moreover, IONP-LPrA2 reduced
PC tumorspheres (treated with 5-FU) via notch signaling
and suggesting that leptin might be involved in reducing
the cytotoxic effect of chemotherapeutic drug and facilitating chemoresistance [71]. The leptin-notch signaling
axis targeting has been projected as potential mediator for
benefitting PC patients with obesity. Overall, the effect of
AdipoQ and leptin in the progression of PC is still under
investigation in obese people and further studies are warranted before targeting these adipokines in PC therapy.
Gut microbiota and inflammation

The gut microbiome (hidden organ) comprises at least
1014 microorganisms belonging mostly to the phyla Firmicutes and Bacteroidetes, which play an important role
in obesity and other metabolic disorders [72]. Recent evidences suggest that diet, environmental factors and microbial components can contribute to the development
of cancer in liver and pancreas through a gut-liver/pancreas axis [73]. As shown in Fig. 3, a high-fat diet can
alter the gut microbiome and trigger an inflammatory
cascade. Gram-negative bacteria secrete lipopolysaccharide (LPS), which induces low-grade inflammation
through its binding to toll-like receptors (TLRs) and
CD14 co-receptors present on monocytes, macrophages
and neutrophils [74, 75]. Furthermore, altered gut
microbiota may lead to decreased intestinal tight junction proteins (ZO-1 and occludin), which allows LPS
entry into circulation [76]. Binding of LPS to its
up-regulated receptors (CD14 or TLRs) on immune cells
induces PC cell proliferation [77, 78]. Additionally, these
immune cells also play a role in cancer cell invasion,
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angiogenesis and metastasis [79–81] by recruiting myeloid differentiation primary response gene 88 (MyD88)
or TIR-domain-containing adapter-inducing interferon-β
(TRIF) adaptor molecules. Activation of these molecules
leads to inflammation by up-regulating p44/42 mitogenactivated protein kinase/extracellular signal-regulated
kinase (MAPK) and NF-κB pathways (Fig. 3). Therefore,
an altered gut microbiota may promote cancer by driving inflammatory responses [82]. In support of this,
germ-free (absent microflora) mice are less prone to carcinogenesis probably due to a decrease in tumorassociated inflammation [83, 84]. Similar results were
observed when WT mice were treated with broadspectrum antibiotics to inhibit the microbiota [85]. As
final evidence, antigenic peptide secreted from Helicobacter pylori (which causes gastric ulcers) has been
associated with PC pathogenesis [86]. H. pylori components translocate into the pancreas from the gut and
activate NF-κB, thereby increasing the expression of
pro-inflammatory cytokines involved in PC initiation
and progression [87]. A recent study by Sethi et al. demonstrated that the gut microbiome modulation may have
impact on tumor growth in a mouse model. Initially, the
authors orally administered a cocktail of broad-spectrum
antibiotics to C57BL/6J mice for 15 days. Then at 15
days, a pancreatic cell line derived from KrasG12D/+;
Trp53R172H/+; Pdx1cre (KPC) mice was injected subcutaneously or intrasplenically (to induce liver metastasis).
Results of this study showed that absence of gut microbiota led to a significant decrease in subcutaneous tumors, and decreased degree of liver metastasis. Besides,
an absence of gut microbiota shows a significant
increase in anti-tumor mature T cells [Th1 (IFN gamma+CD4+CD3+) and Tc1 cells (IFN gamma+CD8+CD3+)]
in the tumor microenvironment with an unknown
mechanism. Finally, the relative abundance of Bacteroidetes and Firmicutes phyla decreased in fecal samples
upon antibiotic administration in KPC mice. The authors concluded that modulation of gut microbiota on
tumor progression could be a novel immunotherapeutic
strategy [88].
In general, pancreatic tumors depend on carbohydrate
metabolism for their survival, growth and resistance to
chemotherapy. Dietary carbohydrates are usually fully metabolized in the small intestine, with the exception of resistant starch. Gut microbiota further process the starch in the
large intestine through fermentation, and as a result,
short-chain fatty acids (acetate, butyrate and propionate)
are released. Resistant starch by avoiding degradation in
small intestine imparts several health benefits via decreasing circulatory glucose levels, body weight, and inflammation without causing any side effects [89]. Interestingly,
media engineered to mimic resistant starch (low glucose
concentration) decreased PC cell proliferation compared
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Fig. 3 Altered gut microbiota is responsible for pancreatic cancer progression. a. High-fat diet intake alters the gut microbiota composition. Altered
gut microbiota secrete lipopolysaccharides (LPS), which enters circulation by damaging intestinal tight junction proteins. Circulatory LPS then binds to
the toll like receptor on immune cells to recruit MyD88 or TRIF adaptor molecules. These molecules further activate MAPK and NF-κB pathways to
activate several inflammatory cytokines, leading to cancer cell proliferation. b. Short-chain fatty acids (SCFAs) are released from resistant starch by the
gut microbiota that enters the circulation. Afterward, SCFAs bind to G-protein-coupled receptors to activate the MAPK signaling pathway, triggering
cancer cell proliferation.

with control media. The decrease in cell proliferation is due
to down-regulation of ERK and mTOR signaling (Fig. 3).
Similarly, mice bearing sub-cutaneous PC tumors fed a resistant starch diet showed lower tumor weight than
controls on a normal diet. Additionally, resistant
starch also inhibits the growth of inflammation-causing organisms including Bacteroides acidifaciens,
Ruminococcus gnavus, Clostridium cocleatum and
Escherichia coli in mice by modulating gut microbiota [90].
Early metastasis (primarily at lymph nodes and liver) and
chemoresistance are responsible for PC aggressiveness.

However, treatment with gemcitabine, first line therapy for
metastatic PC, results in altered gut microbiota, which affects PC growth. Administration of gemcitabine in nude
mice bearing subcutaneous PC cell line tumors leads to increased growth of Proteobacteria and Akkermansia muciniphila, which potentiate inflammation and/or mucin
degradation. The imbalance of gut microbiome due to gemcitabine treatment also disrupts the intestinal integrity; this,
in turn, favors the entry of microorganisms or their components into the circulation to reach distant organs. In the
pancreas, the microbe-associated molecular patterns (such
as LPS and endotoxins) on the microbial surfaces bind to
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TLRs, activating inflammation through NF-kB signaling.
In addition, gemcitabine-treated mice have greater
LPS-induced inflammation and lower levels of inosine
(a naturally occurring metabolite of adenosine), which has
anti-inflammatory and immunosuppressive effects [91].
Furthermore, fecal microbiota obtained from KPC mice
was recolonized into antibiotic treated WT mice which
shows higher bacterial population access into the pancreas. Ablation of gut microbiota in PtflaCre; LSL-KrasG12D
(KC) mice by oral antibiotics were recolonized with feces
derived from WT or KPC mice and pancreatic tumor
growth acceleration was observed in KPC derived feces
only. Similarly, recolonization of feces (from KPC animal
bearing pancreatic tumors) in germ free (GF)-KC mice
shows increased pancreatic tumor growth as compared to
GF-WT mice. This tumor acceleration might be associated with a decrease in activated T-cell infiltration in GF
condition. They hypothesized that antibiotic treatment results in an increased intratumoral CD8:CD4 T-cell ratio
which activates immunogenicity in PC. Future studies are
warranted to identify microbial signatures that influence
growth of PC tumors [92]. Taken together, a better understanding of the role of gut microbiota in PC tumor progression could open up new avenues in PC therapy
development.
In obesity, pro-inflammatory cytokines are released
from AT macrophages and infiltrate into AT; however
the exact mechanism for these events is not known. In
obese rats and humans, elevated inflammatory cytokine
TNF-α activates other cytokines, in particular, IL-6, promoting angiogenesis and metastasis [93–95]. Therefore,
the possible common mechanism by which obesity induces inflammation in several cancers (pancreatic,
lymphoma and glioblastoma) might be through
TNF-α-induced NF-κB signaling [96–98]. In addition,
TNF-α secreted from cancer cells triggers cancer associated fibroblasts to stimulate macrophage infiltration
[99, 100]. This infiltration occurs in several cancers
through TNF-α-induced IL-6 to up-regulate STAT3 signaling [101]. Mice with PC tumors and diet-induced or
genetic obesity expressed significantly higher STAT3 in
the PC tumors. The up-regulation of STAT3 can drive
PC progression through the activation of anti-apoptotic
and proliferative proteins (Bcl-XL, Mcl-1, Survivin,
c-Myc and cyclin D1) as well as matrix metalloproteinases [102–104]. Currently, studies are focused on the
role of AT-derived inflammatory cytokines in modulating signaling pathways that can indirectly influence the
progression of PC.
Glucose metabolic enzymes

Despite the harsh hypoxic environment, PC survives in
part due to expression of HIF1-α, which prevents apoptosis and increases the synthesis of glycolytic enzymes
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and transporter proteins [105]. According to the Warburg effect, the cancer cell depends on glycolysis to produce energy instead of aerobic respiration [106–108].
The most important rate-limiting glycolytic enzymes are
pyruvate kinase (PKM2), which catalyzes the conversion
of phosphoenol pyruvate to pyruvate, and lactate dehydrogenase (LDHA), which then catalyzes conversion
of pyruvate to lactate. The glycolytic pathway releases
high-energy phosphates in the form of nicotinamide adenine dinucleotide, which enters the mitochondria for
energy synthesis. LDHA is overexpressed throughout
carcinogenesis, while PKM2 expression increases during
the transition of cystic lesions to cancer. A possible explanation is that cystic lesions require high levels of
LDHA, which induces PKM2 splicing in a later stage of
tumor proliferation [109]. Furthermore, activation of
EGFR initiates translocation of PKM2 to the nucleus
where it binds to β-catenin, resulting in up-regulation of
cyclin D1, Stat3, Oct4 and HIF, which induce cell proliferation [110, 111]. Therefore, both glycolytic enzymes
(PKM2 and LDHA) are possible targets for PC treatment in preclinical studies.
Hepatocyte growth factor

In addition to adipokines, pre-adipocytes as well as mature AT secrete cytokines and growth factors that have a
role in tumor growth. In pancreatic tumor progression,
cross-talk between PSC and PC is mediated through several growth factors including platelet-derived growth factor, transforming growth factor, vascular endothelial
growth factor and hepatocyte growth factor (HGF) [112,
113]. HGF has received much attention due to its mitogenic signal and its angiogenic effects on AT [114, 115].
In the case of obesity, HGF is released from the AT and
the resulting circulatory levels contribute to pancreatic
cell proliferation [116]. Exogenous supplementation of
HGF induces proliferation in a murine pancreatic cell
line (Pan02) through its receptor c-MET, whereas in the
absence of c-MET, HGF had no direct effects in a murine pancreatic cell line and indirectly inhibited apoptotic
cell death [117]. HGF inhibition by means of neutralizing antibody (AMG102) inhibited tumor growth and
metastasis as compared to gemcitabine treatment [118].
Over expression of c-Met renders PC cells resistant to
gemcitabine and radiation [44, 119] through an unknown mechanism. As one possibility, Cui and
co-workers demonstrated that the Forkhead box M1
(FOXM1) transcription factor regulates c-MET expression via ERK, AKT and STAT3 pathways, creating a
positive feedback loop that promotes tumor growth. Further, inhibition of c-MET, FOXM1, ERK, AKT and
STAT3 signaling pathways with their respective inhibitors abolished the c-MET positive loop [120]. Therefore,
the HGF/c-MET feedback loop regulates tumor
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proliferation, invasion and migration [121] and may be a
novel target for growth factor-induced tumor growth.
Hyaluronan

In obesity, TG accumulates in the pancreas along with
other organs and results in inflammation, higher expression of cytokines and remodeling of extracellular matrix
(ECM). Hyaluronic acid or hyaluronan (HA) is a glycosaminoglycan and ubiquitous component of ECM which
increases interstitial fluid pressure (IFP) and also reduces
entry of chemotherapeutic drugs in PC tumors [122]. In
tumor progression, the cross-talk between cancer cells
and ECM is very important. Normally, HA synthesized
by hyaluronan synthase (HAS) and secreted into the
ECM under controlled conditions. However, increased
expression of HA was observed in insulin-resistant mice
aorta [123] and in the pancreas of diabetic mice [124].
In addition, expression of HA in the ECM is associated
with diet-induced insulin resistance and was reversed
upon treatment with the drug pegylated recombinant
human hyaluronidase (PEGPH20), which improves insulin sensitivity in muscle tissue [125].
The PC stroma cells and the ECM express abundant
HA to maintain a supportive tumor microenvironment
[126]. Binding of HA to its receptors [cluster of
differentiation-44 (CD44) or receptor for HA-mediated
motility (RHAMM)], activates Ras and PI3K signaling,
leading to increased cell proliferation, migration, and
metastasis. Further, the activated PI3K pathway in cancer
cells also increases drug resistance via activation of a
multi-drug receptor [127–129]. The HA receptor CD44/
RHAMM mediates cell-cell/matrix interactions and
up-regulation of HA (around 12-fold increase) is observed in PC [130–133]. PC cells increase expression of
HA via epigenetic regulation (decreased DNA methylation) and concomitant up-regulation of its enzyme HAS
[134]. HA exists in low and high molecular weight
forms. In vitro treatment with low molecular weight HA
(25-75 kDa) increased PC cell motility compared to
treatment with high molecular weight HA (400-600
kDa) [135, 136]. In conclusion, inhibition of HA synthesis may be a possible therapeutic strategy against PC and
obesity-associated PC. Recently, PEGPH20 has gained
interest to target HA for improving intratumoral microenvironment in PC. The different concentrations of HA
along with mouse PC cells were implanted in immunodeficient mice that showed high IFP which reduce delivery of chemotherapeutic drugs. So targeting HA, a single
high dose of PEGPH20 had a significant reduction on
IFP in KPC mice. Further, a combination of PEGPH20
and gemcitabine showed decrease in cell proliferation
and increased apoptosis in KPC mice [137]. In a randomized phase II clinical study, metastatic PC patients
(231 were selected from a total of 279 patients) were
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treated with nab-paclitaxel/gemcitabine (AG) or
PEGPH20 + nab-paclitaxel/gemcitabine (PAG). Patients
(n=84) who had HA-high tumors showed improvement
in the progression-free survival, overall survival and reduction in the thromboembolic (TE) incidence by PAG
alone. Furthermore, PAG treatment was accompanied by
more muscle spasm, neutropenia, myalgia and TE as
compared to AG. Overall, srudy finding suggested that
tumor HA could be a promising therapeutic target for
PC patients with high HA [138].
Diabetes mellitus associated pancreatic ductal
adenocarcinoma

Obesity is associated with insulin resistance and T2DM,
which in turn is a potential risk factor for PC. In a
post-prandial state, insulin maintains the levels of circulating glucose and FFAs. Insulin resistance is a condition
in which the adipose and muscle tissues and to a lesser
extent the pancreas, brain, liver and kidney are unable to
respond to insulin. Insulin resistance is a hallmark of
T2DM, leading to down-regulation of insulin signaling
pathways (at the post-receptor level) in these tissues
[139]. Of the diabetic population, 12% are diagnosed
with type 1 diabetes, 80% with T2DM, and 8% with pancreatic diabetes (acute and chronic) [140]. About 80% of
the PC population have insulin resistance or frank diabetes and are diagnosed at the metastasis stage. However, recent-onset diabetic patients developing diabetes
at later age (average age greater than or equal to50) accompanied with weight loss and exceesive exocrine damage (PC associated diabetes mellitus) were higher risk
for PC than long term diabetic population [141].
Pharmacological therapies like metformin (lowers blood
glucose and insulin levels), sulfonylurea (promotes secretion of insulin from the pancreas) and insulin analogues
(glargine) are available to treat diabetes [142, 143]; however these treatments often fail after prolonged usage.
However, a case-control study at M.D. Anderson Cancer
Center from 2004 to 2008 recruited 973 PDAC patients
among them 259 were diabetic. The diabetic patients
who received metformin had a lower risk of PC compared to those who were not given metformin; whereas,
insulin or insulin secretagogues administered diabetic
patients had a higher risk of PC [144].
As mentioned, T2DM is also a major risk factor for
several cancers including PC. Epidemiological studies indicate that T2DM patients have a 1.8-fold increased risk
for PC development [145]. However, the literature
suggests that insulin resistance and diabetes may be a
consequence of PC (up to 50-80% of cases). Clinical
studies reveal that 0.85% (8 out of 2122) to 7% (6 out of
86) of diabetic patients were first diagnosed with PC
[146, 147]. In PC, the increase in circulatory FFAs secreted from AT causes lipotoxicity in β-cells, resulting in
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PC-associated diabetes mellitus (PCDM) [145, 148, 149].
After tumor resection, the increased survival of PC patients was associated with greater insulin sensitivity
[150]. Recently, the American Diabetic Association classified PCDM, which is induced by chronic pancreatitis
and pancreatic surgery, as type3c diabetes mellitus [151].
Still, evidence describing how diabetes leads to PC or
vice versa is lacking. Some of the key molecules secreted
from AT are being considered for the treatment of
PCDM, which we focus on below.
Adrenomedullin and extracellular vesicles (exosomes)

Adrenomedullin (AM) is expressed by F-cells of the pancreas and plays a role in PC along with its receptor
(adrenomedullin receptor ADMR). In 1993, AM was initially isolated from an adrenal medulla tumor called a
pheochromocytoma. It is also expressed in AT and acts
on pancreatic β-cells to inhibit insulin secretion; however, its effects on β-cells are poorly understood [152].
The circulatory levels of AM are very low under normal
conditions; however, its levels are elevated in PC to
cause insulin resistance [153]. Pancreatic beta, endothelial and stellate cells express ADMR. Its autocrine function in modulating tumor growth and progression has
been evaluated in certain PC cell lines, i.e. Panc-1,
BxPC3, and MPanc96 as well as human PSC and endothelial cells [154]. In a study, treatment with AM antagonist reduced PC tumor growth which indicating that
AM plays a role in promoting PC progression. Furthermore, silencing of ADMR inhibited tumor growth and
metastasis in liver and lung tissues of xenograft mice
[155]. In PCDM, plasma levels of AM were significantly
higher compared to diabetic patients alone, and its expression is higher in tumor and hypoxia conditions [152, 156].
AM is transported in the pancreas by extracellular vesicles, which contain proteins, lipids, and nucleic acids
and are secreted by all cell types into circulation [157].
These vesicles play an important role in the transportation of biological components to other cells and tissues
[158]. Extracellular vesicles form exosomes (30-100 nm)
by inward or reverse budding of vesicular bodies called
microvesicles (100-1000 nm) or by outward blebbing of
membrane and apoptotic bodies (500-2000 nm) [159,
160]. Exosomes derived from PC cells have the capacity
to promote metastasis in a tissue such as liver by residing in a pre-metastatic niche. The niche contains macrophage migration inhibitory factor engulfed by Kupffer
cells, which induces secretion of fibronectin in the liver.
The secreted fibronectin inhibits infiltration of macrophages and neutrophils derived from the bone marrow
and promotes tumor growth [161]. PC exosomes control
the specific site of organ metastasis by producing integrins, molecules that mediate cell adhesion. For example,
Kupffer, lung fibroblast and epithelial cells recognize
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integrins such as αvβ5, α6β1 and α6β4, respectively, and
subsequently recruit PC cells to these organs [162]. PC
exosomes can also transfer AM to pancreatic β-cells (via
caveolin-dependent endocytosis and micropinocytosis),
which causes insulin resistance through ADMR-AM interactions. Furthermore, the presence of exosomal AM
results in β-cell damage by increasing the production of
reactive oxygen/nitrogen species and by increasing endoplasmic reticular stress markers (Bip and Chop) [163].
PC cell exosomes containing AM enter AT by the same
mechanism that occurs in pancreatic β-cells. Internalization of AM results in lipolysis by activation of
hormone-sensitive lipase through p38 and MAPK/ERK
pathways; the resulting effect is growth and differentiation of the cancer cells [164]. Another similar peptide
to AM is AM-2, which was identified in rats in 2004.
AM2 has a similar function as AM in promoting angiogenesis, tumor development, progression and metastasis
through MAPK signaling [165]. However, no studies
have examined the role of AM-2 in PCDM.
Vanin and matrix metalloproteinase

Another important molecule is vanin 1 (VNN1, pantetheinase) present on the surface of epithelial and myeloid cells and highly expressed in the gut and liver tissue
[166, 167]. VNN1 is mainly responsible for the breakdown of pantetheine to pantothenic acid (vitamin B5)
and cysteamine [168]. It is actively involved in inflammation, migration, stress, and glucose and lipid metabolism.
Alteration of glucose and lipid metabolic pathways in
the liver leads to development of insulin resistance and
eventual T2DM. Mice exhibiting diet-induced obesity
and Zucker diabetic fatty rats (model for T2DM) have
more VNN1 activity in plasma as well as higher expression in the liver compared to normal controls [169].
Based on gene expression profiling, PCDM patients express higher VNN1 and MMP9 levels in peripheral
blood as compared to patients with T2DM alone [170].
VNN1 reduces inflammation in PCDM by altering the
levels of cysteamine and glutathione. VNN1 along with
cysteamine protect the pancreatic β-cells from the oxidative stress generated during streptozotocin-induced
diabetes in animals [171]. Enhanced γ-glutamylcysteine
synthetase activity observed in vanin-1-/- deficient mice
with low levels of cysteamine resulted in an accumulation of endogenous glutathione (GSH) levels [172, 173].
By contrast, over expression of VNN1 decreased expression of GSH and PPARγ, resulting in increased oxidative stress in PCDM [174], through an unknown
mechanism. These findings suggest that decreased GSH
and PPARγ might contribute to islet dysfunction in
PCDM and that vanin-1 and MMP9 could serve as novel
pharmacological targets to treat early asymptomatic
PCDM patients.
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Impact of obesity and diabetes on acinar, ductal and islet
cells

The pancreas islets, acinar cells, and ducts of the gland
make up approximately 2-3%, 85% and 5% of the volume, respectively. Similar to other organs, pancreas size
is regulated by genetic as well as environmental factors
(food intake) [175]. Feeding chronic high fat diet to
Zucker diabetic fatty rats (model for both obesity and
T2DM) showed excessive fat accumulation in pancreatic
acinar cells and later resulted in acinar cell injury and
pancreatic fibrosis [176]. In another study, feeding high
fat or high calorie-diets to Pdx-1Cre and LSL-KrasG12D
mice caused increased PSC activation, stromal fibrosis
and infiltration by inflammatory cells [177]. In case of
T2DM, both islets and peri-islet exocrine tissue of pancreas have an activated PSC. The activated, as well as
quiescent PSC express receptors for insulin and
insulin-like growth factor, however in activated PSC; insulin enhances cell proliferation and production of
extracellular matrix proteins as compared to quiescent
PSC [178]. Moreover, obese and T2DM patients show a
ten-folds and four-folds increase in pancreatic ductal cell
replication (more Ki67 expression), respectively. The increased pancreatic ductal cell replication is a risk factor
towards pancreatitis and pancreatic cancer in obesity
and or type 2 diabetes subjects [179].

Obesity and diabetes associated PC stem cells

Studies are suggesting that tumor initiation, progression,
and resistance to chemotherapy is due to the presence of a
small subset of a cell population within the tumor called
cancer stem cells [180–182]. The presence of stem cell
markers in normal pancreas might be involved in the progression of PC and resistance to drugs [183]. In obesity, leptin treatment affected PC progression and increased
pancreatic cancer stem cell markers such as CD24/CD44/
ESA, ALDH, CD133, and Oct-4. Further, the expression of
leptin receptor was decreased by tumor suppressor micro
RNAs that specifically target pancreatic stem cell markers
(Met, ABCB1, and CD44) to reduce their expression [184].
Leptin is also involved in the growth of PC tumorspheres
and resistance to the chemotherapeutic drug (gemcitabine)
[185] by increasing the stem cell markers (CD24, CD44,
ESA, CD133, and ALDH) in MiaPaCa-2 PC cell line. Additionally, leptin up-regulates the expression of ABCB1 (an
ATP binding transporter protein) in PC tumorspheres
suggesting its role in stem cell stimulation and chemoresistance [70]. In case of diabetic population, hyperglycemia is a hallmark of T2DM which stimulates PC by
promoting a epithelial to mesenchymal transition and
expression of pluripotency stem cell markers (Sox2, Oct4,
and Nanog) via activating transforming growth factor-beta
1 [186]. Further, studies are needed to understand the
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exact molecular mechanisms involved in metabolic diseases associated with PC stem cells.

Conclusions
Several studies suggest that obesity and T2DM increase
the risk for PC development and its pathogenesis. However, mechanistic interplay responsible for development
and progression of pancreatic tumor remains obscure. Recent studies on key players associated with obesity and
diabetes such as adipocytokines, gut microbiota, adrenomedullin, hyaluronan, vanin and matrix metalloproteinase
have deciphered unknown linkage present across PC as
well as PCDM. These mediators play central role in promoting obesity-and diabetes-associated pancreatic cancer,
however, to date studies involving therapeutic targeting
and harnessing their biomarker potential are still in infancy. Henceforth, based on literature survey, we suggest
that there is an urgent need to delineate biomarkers as
well as therapeutic target(s) involved in the obesity and
T2DM associated PC development making inroads to prevent this highly lethal malignancy.
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